AR131299A1 - New IAP inhibitors, methods for manufacturing them, and their uses - Google Patents
New IAP inhibitors, methods for manufacturing them, and their usesInfo
- Publication number
- AR131299A1 AR131299A1 ARP230103330A ARP230103330A AR131299A1 AR 131299 A1 AR131299 A1 AR 131299A1 AR P230103330 A ARP230103330 A AR P230103330A AR P230103330 A ARP230103330 A AR P230103330A AR 131299 A1 AR131299 A1 AR 131299A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacturing
- formula
- methods
- compound
- tautomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto caracterizado por la siguiente fórmula (1) o una sal farmacéuticamente aceptable del mismo, tautómero, profármaco o metabolito. Un compuesto de fórmula (2) o una sal farmacéuticamente aceptable del mismo, tautómero, profármaco o metabolito. Una composición farmacéutica o kit que comprende el compuesto, sal farmacéuticamente aceptable del mismo, tautómero, profármaco o metabolito de acuerdo con una cualquiera de las reivindicaciones anteriores. Un proceso para fabricar un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 16, que comprende el paso de hacer reaccionar el producto intermedio de fórmula (1-1) con un compuesto intermedio de fórmula (1-2) para obtener el compuesto intermedio de fórmula (1-3) y el paso de someter el producto intermedio (1-3) a desprotección, en donde R¹, R², R²ᵃ y R³ tienen los mismos significados que los especificados en cualquiera de las reivindicaciones 1 a 16 anteriores.A compound characterized by the following formula (1) or a pharmaceutically acceptable salt, tautomer, prodrug or metabolite thereof. A compound of formula (2) or a pharmaceutically acceptable salt, tautomer, prodrug or metabolite thereof. A pharmaceutical composition or kit comprising the compound, pharmaceutically acceptable salt, tautomer, prodrug or metabolite according to any one of the preceding claims. A process for manufacturing a compound according to any one of claims 1 to 16, comprising the step of reacting the intermediate of formula (1-1) with an intermediate of formula (1-2) to obtain the intermediate of formula (1-3) and the step of subjecting the intermediate (1-3) to deprotection, wherein R¹, R², R²ᵃ and R³ have the same meanings as specified in any one of claims 1 to 16 above.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22212550 | 2022-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131299A1 true AR131299A1 (en) | 2025-03-05 |
Family
ID=84487467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230103330A AR131299A1 (en) | 2022-12-09 | 2023-12-07 | New IAP inhibitors, methods for manufacturing them, and their uses |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR131299A1 (en) |
| TW (1) | TW202432110A (en) |
| WO (1) | WO2024121395A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SI2139490T1 (en) * | 2007-04-13 | 2014-11-28 | The Regents Of The University Of Mchigan Office Of Technology Transfer, University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| CA2896577C (en) * | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| US10300074B2 (en) | 2014-06-04 | 2019-05-28 | Sanford Burnham Prebys Medical Discovery Institute | Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy |
-
2023
- 2023-12-07 AR ARP230103330A patent/AR131299A1/en unknown
- 2023-12-08 WO PCT/EP2023/084910 patent/WO2024121395A1/en not_active Ceased
- 2023-12-08 TW TW112147924A patent/TW202432110A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202432110A (en) | 2024-08-16 |
| WO2024121395A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114922A1 (en) | MOLECULES THAT HAVE PESTICIDAL UTILITY, AND COMPOSITIONS AND PROCESSES, RELATED TO THEM | |
| CL2009000780A1 (en) | Substituted heterocyclyl-pyran-heterocyclyl, heterocyclyl-oxepine-heterocyclyl, benzopyran-heterocyclyl and substituted benzoxepine-heterocyclyl derived compounds; pharmaceutical composition; process for preparing the composition; pharmaceutical kit; and its use in the treatment of cancer, mediated by the inhibition of pi3k. | |
| AR128931A1 (en) | COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF | |
| JP2020536082A5 (en) | ||
| AR056873A1 (en) | DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS QUINASA INHIBITORS OF CYCLINE DEPENDENTS, PHARMACEUTICAL COMPOSITIONS | |
| BR112015028501B8 (en) | BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT | |
| AR043822A1 (en) | DOSAGE FORMS AND TREATMENT PROCEDURES USING VEGFR INHIBITORS | |
| CO2021014210A2 (en) | Pyrrole compounds | |
| UY39642A (en) | ANTIVIRAL HETEROCYCLIC COMPOUNDS | |
| PE20250667A1 (en) | SOLID FORMS, SALTS AND PREPARATION PROCESSES OF A CDK2 INHIBITOR | |
| AR128066A1 (en) | HETEROCYCLIC PYRIMIDINE COMPOUND AND METHOD OF PREPARATION AND MEDICAL USE THEREOF | |
| AR129003A1 (en) | HETEROCYCLIC ANTIVIRAL COMPOUNDS | |
| CO2022008616A2 (en) | Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor | |
| CL2023003921A1 (en) | Transglutaminase inhibitors | |
| AR131299A1 (en) | New IAP inhibitors, methods for manufacturing them, and their uses | |
| CO2025016753A2 (en) | gsk3α inhibitors and methods of their use | |
| CR20250124A (en) | Compounds for treating cancer | |
| AR129185A1 (en) | 6-(PYRIMIDIN-4-YL)QUINOLINE COMPOUNDS SUBSTITUTED AS CYCLIN-DEPENDENT KINASE INHIBITORS | |
| AR107937A1 (en) | CINOLIN-4-AMINA COMPOUNDS AND ITS USE IN CANCER TREATMENT | |
| AR060690A1 (en) | POLYMERS CONTAINING MAGNESIUM FOR HYPERPHOSPHATEMIA | |
| AR127165A1 (en) | RESMETIROM TO REDUCE LIVER VOLUME | |
| DOP2025000146A (en) | PROTAC CHIMEROUS COMPOUND, METHOD OF PREPARATION THEREOF AND USE THEREOF | |
| CL2023003979A1 (en) | Transglutaminase inhibitors | |
| AR128100A1 (en) | COMPOUNDS FOR THE TREATMENT OF HAIR LOSS | |
| ECSP24007534A (en) | TRANSGLUTAMINASE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |